Wyeth Seeking "Novel" Partnerships For Oncology Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
The company has 13 drugs in development for oncology indications, "far more" than it can afford to develop on its own. Wyeth is not interested in out-licensing or divesting the candidates but instead will pursue a "novel" development partnership.